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Abstract
Background: Case-management with artemether-lumefantrine (AL) is one of the key strategies
to control malaria in many African countries. Yet, the reports on translation of AL implementation
activities into clinical practice are scarce. Here the quality of AL case-management is reported from
Uganda; approximately one year after AL replaced combination of chloroquine and sulphadoxine-
pyrimethamine (CQ+SP) as recommended first line treatment for uncomplicated malaria.
Methods: A cross-sectional survey, using a range of quality of care assessment tools, was
undertaken at all government and private-not-for-profit facilities in four Ugandan districts. Main
outcome measures were AL prescribing, dispensing and counseling practices in comparison with
national guidelines, and factors influencing health workers decision to 1) treat for malaria, and 2)
prescribe AL.
Results: 195 facilities, 232 health workers and 1,763 outpatient consultations were evaluated. Of
1,200 patients who needed treatment with AL according to guidelines, AL was prescribed for 60%,
CQ+SP for 14%, quinine for 4%, CQ for 3%, other antimalarials for 3%, and 16% of patients had no
antimalarial drug prescribed. AL was prescribed in the correct dose for 95% of patients. Only three
out of seven AL counseling and dispensing tasks were performed for more than 50% of patients.
Patients were more likely to be treated for malaria if they presented with main complaint of fever
(OR = 5.22; 95% CI: 3.61–7.54) and if they were seen by supervised health workers (OR = 1.63;
95% CI: 1.06–2.50); however less likely if they were treated by more qualified health workers (OR
= 0.61; 95% CI: 0.40–0.93) and presented with skin problem (OR = 0.29; 95% CI: 0.15–0.55). AL
was more likely prescribed if the appropriate weight-specific AL pack was in stock (OR = 6.15; 95%
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Malaria Journal 2008, 7:181 http://www.malariajournal.com/content/7/1/181CI: 3.43–11.05) and when CQ was absent (OR = 2.16; 95% CI: 1.09–4.28). Routine AL
implementation activities were not associated with better performance.
Conclusion: Although the use of AL was predominant over non-recommended therapies, the
quality of AL case-management at the point of care is not yet optimal. There is an urgent need for
innovative quality improvement interventions, which should be rigorously tested. Adequate
availability of ACTs at the point of care will, however, ultimately determine the success of any
performance interventions and ACT policy transitions.
Background
Forty-one African countries with endemic Plasmodium fal-
ciparum malaria have recently changed antimalarial drug
policies from ineffective monotherapies to highly effica-
cious artemisinin-based combination therapy (ACT); and
among them, 21 countries selected artemether-lumefan-
trine (AL) as their first-line ACT for uncomplicated
malaria [1]. In Uganda, resistance to chloroquine (CQ)
and sulphadoxine-pyrimethamine (SP) monotherapies
progressed rapidly during the 1990's [2,3] and the efficacy
of the subsequent recommendation of a combination of
CQ and SP (CQ+SP) was soon compromised [4,5]. In
2004 the decision was made to abandon CQ+SP in favour
of AL, however the policy was subsequently revised to
include another ACT combination of artesunate and amo-
diaquine (AS+AQ) as an alternative treatment when AL is
not available [6]. Quinine was recommended as the sec-
ond-line treatment, SP was reserved only for intermittent
preventive treatment in pregnancy, and CQ+SP was no
longer recommended for the treatment of malaria.
During 2005 and 2006, the Ugandan Ministry of Health
implemented the new treatment policy and this process
included four key activities. First, national malaria case-
management guidelines were revised to incorporate
changes in treatment recommendations [7]. Second,
between January and May 2006, all government and pri-
vate-not-for-profit facilities received AL supplies to ensure
adequate stocks prior to delivery of the in-service training
at the periphery. AL was delivered in the standard four
weight-specific blister packages each containing a differ-
ent number of the same strength tablets. At all facilities AL
was provided free of charge, and by the time of our study,
there were no deliveries of AS+AQ to health facilities.
Third, in-service training for health workers was con-
ducted to implement new guidelines. The rapid cascade
training-programme started in February with a national,
two-day workshop for 588 senior district health workers
who were responsible for the training of all front-line
health workers by the end of May 2006. The training for
front-line health workers focused on the management of
uncomplicated malaria, was organized over one-day at
health facilities, and included lectures without practical
case scenarios or clinical practice. No training evaluation,
further follow up, or supervisory visits of health workers
who attended trainings were undertaken. Finally, wall
charts reflecting AL case-management recommendations
were developed to serve as job-aids [8]. These charts,
together with new guidelines, were delivered to health
workers either through district health management teams
or during the training sessions.
Effective translation of new guidelines into clinical prac-
tice is of critical importance to maximize the potential
impact of improved, efficacious therapies. However, there
are very few reports on the quality of clinical practices fol-
lowing implementation of AL policies in Africa [9,10].
Here AL case-management practices in accordance with
national case-management guidelines are reported
approximately 1 year after AL was distributed, training of
health providers completed and guidelines and wall
charts delivered to peripheral facilities across Uganda.
Methods
Study design and data collection
A cross-sectional, cluster sample survey was conducted
between 29 May and 16 August 2007 at all government
and private-not-for profit health facilities in four districts
purposively selected to represent diversity of malaria
transmission in Uganda: Apac, rural holoendemic district;
Tororo, rural hyperendemic district; Mubende, rural mes-
oendemic district; and Jinja, periurban mesoendemic dis-
trict [11]. A cluster was defined as all consultations for sick
patients presenting at each facility on a randomly selected,
single survey day. Patients coming for follow up visits for
chronic diseases (e.g. TB, diabetes), traumas, burns, and
patients referred or admitted for hospitalization were not
recruited.
Sixteen nurses in eight survey teams collected data. In each
district training and concordance testing was undertaken
over five days until the agreement of practice results of
nurses and trainers was greater than 90%. At health facili-
ties data were collected using a range of quality of care
assessment methods. All adult patients and caretakers of
sick children were interviewed and had limited clinical
screening when they completed their health facility visit
and were ready to leave. Prior to the interviews, written
informed consent to be enrolled in the study was
obtained from all patients or their caretakers. InterviewersPage 2 of 10
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lary temperature, main complaints, prior use of antima-
larial drugs, routine counseling and drug dispensing
practices undertaken during the facility visit, and if the
visit was an initial or follow-up consultation. Information
was also collected from patient-held records about rou-
tine diagnostic procedures requested, results reported and
medications prescribed.
At the end of the survey day all health workers who had
attended study patients were interviewed to collect infor-
mation on their demographics, pre-service and in-service
training, working experience, access to national guidelines
and exposure to supervision in the preceding six months.
Finally, a health facility assessment was undertaken to
record the availability of AL and other antimalarials on
the survey day and in the past 6 months, the presence of
functional weighing scales, thermometers, malaria diag-
nostics, and any displayed case-management wall charts.
In addition, malaria treatments prescribed during the
week prior to the survey were documented from the
patients' registers held at the clinic.
Definitions
Study definitions reflected national malaria case-manage-
ment recommendations from the latest Ugandan "Guide-
line for Health Workers on the Management of Uncomplicated
Malaria" [7], "Guidelines for Integrated Management of
Childhood Illnesses" [12] and "Flowcharts for Management of
Malaria" [8]. In summary, according to these guidelines
and flowcharts any patient presenting with fever or history
of fever in absence of danger signs and prior, correct use
of ACTs should be presumptively treated with recom-
mended first line treatment for uncomplicated malaria.
The guidelines provide the same recommendations across
all age groups. The use of malaria microscopy is discour-
aged for most febrile patients with the exception of special
patient groups such as suspected treatment failures, severe
cases, children below 5 kg and pregnant women. A case of
patient needing management with AL was defined as a
non-pregnant patient, weighing 5 kg and above, who pre-
sented to a health facility for an initial visit with a history
of fever during the present illness or axillary temperature
≥ 37.5°C, and treated as an outpatient in the absence of a
negative routine malaria test and prior use of ACT.
The correctness of AL dosage prescriptions was assessed in
accordance with guidelines dosage recommendations for
four weight-specific AL categories [7] and was classified
into three categories: 1) recommended (one tablet twice a
day over three days for a 5–14 kg patient; two tablets twice
a day over three days for a 15–24 kg patient; three tablets
twice a day over three days for a 25–34 kg patient; and
four tablets twice a day over three days for a patient 35 kg
and above, 2) overdosed, and 3) underdosed prescrip-
tions. The quality of AL dispensing and counseling for
patients included the performance of the following seven
tasks: weighing of patients, explanation on how to take AL
at home, administration of the first dose at health facility,
observation of the swallowing of the first dose, and provi-
sion of advises to take AL after the meal, to complete all
doses, and what to do in case of vomiting.
Statistical analysis
Data were double-entered into Microsoft Access 2000
(Microsoft Inc, Redmond, Washington). Questionnaires
were entered twice by two independent data entry clerks,
and data files were compared for errors using a verifica-
tion programme and referring to original questionnaires.
All analyses were performed using STATA, version 8
(StataCorp, College Station, Texas). Results from four dis-
tricts were combined and descriptive analysis was under-
taken at the health facility, health worker, and patient
level across all age groups and stratified for children below
5 years of age and patients 5 years and older. A stepwise
approach was applied in analyzing quality of malaria
case-management for patients who needed to have AL pre-
scribed according to guidelines. First, to assess overall per-
formance of the new policy, treatment practices were
analyzed at all health facilities regardless of the availabil-
ity of AL. Then, to assess health workers adherence to the
new policy analysis was restricted to facilities where AL
was in stock on the day of the survey. Finally, at facilities
with available AL, the quality of AL dosage prescriptions,
and the quality of dispensing and counseling practices
was respectively restricted to patients who had AL pre-
scribed and to those who had both, AL prescribed and dis-
pensed at facility. Data are presented as frequencies and
proportions, with corresponding 95% confidence inter-
vals (CIs) adjusted for clustering by health facility.
Two outcomes were selected to examine factors influenc-
ing health workers adherence to guidelines at facilities
where AL was in stock. These included health workers
decision to 1) treat for malaria, and 2) select AL as the rec-
ommended drug. The following factors were examined:
health workers pre-service training; in-service training on
the use of AL; access to national malaria guidelines; pres-
ence of AL wall charts; availability of CQ; availability of
weight-specific AL packs; supervision including AL
(defined as at least one supervisory visit in past 6 months
including any discussion on appropriate use of AL); the
patient's age; and main complaints of fever, cough, and
skin problem. Interaction terms between in-service train-
ing and all factors of programmatic importance were also
tested for each of two outcomes. The association between
factors and outcomes was examined applying logistic
regression modeling with the STATA xtgee procedure using
an exchangeable working correlation matrix to account
for correlated nature of data [13]. For each outcome thePage 3 of 10
(page number not for citation purposes)
Malaria Journal 2008, 7:181 http://www.malariajournal.com/content/7/1/181odds ratio (OR), 95% confidence interval and P-values
were first estimated for each factor in a series of univariate
models. All factors with P-value for association < 0.15
were then entered into multivariate model, and a back-
ward, stepwise strategy was used to eliminate variables
with P-value > 0.05. Hypothesis testing and confidence
interval estimation were done with an alpha level of 0.05.
Ethical approval
The ethical approval for this study was provided by the
Uganda National Council for Science and Technology
(reference number HS 275).
Results
Description of the sample
All 195 health facilities which were open during the sur-
vey period in study districts were assessed. At seven facili-
ties, a health facility assessment was undertaken but no
consultations took place during the survey day. At the
remaining 188 facilities, outpatient malaria case-manage-
ment practices were evaluated on 1,766 consultations
undertaken by 233 health workers. No health worker,
adult patient or caretaker on behalf of sick child refused to
participate in the study. However, of 233 health workers,
one (0.4%), who performed three consultations, had to
urgently leave the facility before an interview could be
performed. Of the 1,763 consultations analyzed, 1,200
consultations met our definition of patients who needed
AL management in accordance with national guidelines
(461 < 5 years and 739 ≥ 5 years of age). The remaining
563 consultations were for patients < 5 kg (10), pregnant
women (74), follow up visits (94), had neither a history
of fever nor temperature ≥ 37.5°C (371), had received AL
prior to coming to facility (47), or had negative malaria
slide reported through routine practices (85).
Health facility and health worker characteristics
Of the 195 health facilities assessed, most (90%) were
smaller health centres II and III, and most facilities were
run by the government (88%) (Table 1). The majority had
functional weighing scales (91%) and thermometers
(75%) while malaria microscopy was provided at only
26% of facilities. Only one facility stocked malaria rapid
diagnostic tests. Nearly half of facilities (93/195; 48%)
Table 1: Characteristics of the health facilities in study districts in Uganda
Characteristics (N = 195) n (%)
Health facility type
Hospital 8 (4.1)
Health centre IV 12 (6.2)
Health centre III 56 (28.7)
Health centre II* 119 (61.0)
Health facility ownership
Government 172 (88.2)
Non-government 12 (6.2)
Mission 11 (5.6)
Equipment and services at health facility
Weighing scale 178 (91.3)
Thermometer 146 (74.9)
Functional microscopy 50 (25.6)
Wall charts exposed
Any chart recommending artemether-lumefantrine use 93 (47.7)
Chart on uncomplicated malaria 68 (34.9)
Chart on new treatment policy 35 (18.0)
Integrated management of childhood illnesses chart 33 (16.9)
Availability of artemether-lumefantrine on the survey day
Any tablets of artemether-lumefantrine 169 (86.7)
Artemether-lumefantrine 6 tablets pack 162 (83.1)
Artemether-lumefantrine 12 tablets pack 140 (71.8)
Artemether-lumefantrine 18 tablets pack 75 (38.5)
Artemether-lumefantrine 24 tablets pack 124 (63.6)
Availability of other antimalarial drugs on the survey day†
Chloroquine (any formulation) 149 (76.8)
Sulphadoxine-pyrimethamine (any formulation) 170 (87.6)
Quinine (tablets) 58 (29.9)
Amodiaquine (any formulation) 4 (2.1)
Artesunate tablets 8 (4.1)
* This category includes 3 clinics of similar service capacity as health centre II
† Denominators for these variables do not include one health facility with missing valuePage 4 of 10
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of AL, most commonly the chart on management of
uncomplicated malaria (68/93; 73%). Only 17% of facil-
ities had IMCI charts revised to recommend AL use.
On the survey day, any tablet packs of AL were in stock at
87% of facilities, the availability ranging from 39% for 18
tablet packs to 83% for 6 tablet packs (Table 1). All four
weight-specific AL packs were available at only 67 (34%)
facilities. Other antimalarial drugs recommended for
treatment of uncomplicated malaria such as quinine,
artesunate and amodiaquine were respectively in stock at
only 30%, 4%, and 2% of facilities. Conversely, non-rec-
ommended antimalarials were widely available; CQ at
77% and SP at 88% of facilities. Of 157 facilities where
retrospective stock-out data were available, the stock-outs
of AL during the six-month period prior to the survey were
common: 75% of facilities experienced stock-out of at
least one of four AL tablet packs; between 44% and 68%
reported stock-outs for specific AL packs; and 35% of facil-
ities were found to have simultaneous stock-out of all four
packs. In these facilities, the median number of the stock-
out days without any AL was 60 [IQR: 27–113] or 33% of
study time. During the same retrospective period, CQ was
rarely out of stock (23%), while most facilities reported
stock-outs of quinine (58%), artesunate (98%) and amo-
diaquine (98%).
Of 232 interviewed health workers, the most common
cadre performing consultations were nurses (35%); 24%
were clinical officers and doctors; 4% midwives; and fur-
ther 38% of health workers were health workers without
formal clinical training, most commonly nurse aids and
nursing assistants (Table 2). The majority of health work-
ers (182/232; 79%) were trained on AL use, most com-
monly through the MoH cascade in-service training
programme (124/182; 68%). The coverage of health work-
ers trained on IMCI was high (160/232; 69%), however
only 9 of these health workers attended recent IMCI train-
ings that included AL recommendations. Overall, higher
cadres of health workers were more likely to have been
exposed to AL training (86% of clinical officers and doc-
tors vs 82% of nurses and midwives vs 71% of those with-
out formal clinical training). 68% of health workers had
access to national AL guidelines and 54% had access to
IMCI chart booklets which were, however, not revised to
include AL treatment recommendations. More than half
(52%) of health workers reported at least one supervisory
visit in past six months that included discussion on any
clinical topic, however only 34% health workers reported
a visit that included topic on appropriate use of AL.
Quality of AL prescribing, dispensing and counseling 
practices
Of 1,200 patients weighing 5 kg and above who needed
treatment with AL according to guidelines and presenting
to all study facilities, AL was prescribed for 60% of
patients, CQ+SP for 14%, quinine for 4%, CQ for 3%, and
various other antimalarials for 3% of patients (Table 3).
Notably, among all patients 16% left the facility with no
antimalarial prescription, similar in children < 5 years
(14%) compared to patients 5 years and older (17%). At
the same facilities, the retrospective one-week review of
18,917 antimalarial prescriptions adjusted for the same
rate of non-treated febrile patients as observed on the sur-
vey day (16%), suggested somewhat lower use of AL
(52%), similar use of CQ+SP (13%), and more common
prescriptions of quinine (7%), CQ (7%) and SP (4%).
Surprisingly, at facilities where AL was in stock on the day
of the survey, only minor and statistically non-significant
changes in health workers adherence to the new policy
were observed compared to practices at all facilities: AL
prescribing increased by 4% (60 to 64%), use of CQ+SP
decreased by 3% (14 to 11%), other antimalarials for only
1% (10 to 9%), and the proportion of patients not treated
with any antimalarial drugs remained exactly the same
(16%) (Table 3).
Among 714 patients who had AL prescribed and for
whom dosing prescriptions were complete (7 missing val-
ues), 676 (95%) were prescribed recommended AL
weight-specific dosages while overdose and underdose
prescriptions were very rare (16/714; 2% and 22/714; 3%
respectively). High rates of recommended dosage pre-
scriptions were observed across all weight groups: 5–14 kg
(273/283; 97%), 15–24 kg (79/89; 89%), 25–34 kg (10/
Table 2: Characteristics of the health workers in study districts 
in Uganda
Characteristics (N = 232) n (%)
Pre-service training
Doctor 3 (1.3)
Clinical officer 52 (22.4)
Nurse 80 (34.5)
Midwife 9 (3.9)
Cadre without formal clinical training* 88 (37.9)
In-service training on malaria
Any training including artemether-lumefantrine 182 (78.5)
MoH training on artemether-lumefantrine 124 (53.5)
On-job training on artemether-lumefantrine 107 (46.1)
IMCI training including artemether-lumefantrine† 9 (3.9)
Any IMCI training 160 (69.0)
Possession of guideline document
Any guideline including artemether-lumefantrine 158 (68.1)
Management of uncomplicated malaria 153 (66.0)
New policy for uncomplicated malaria 58 (25.0)
Any supervisory visit including appropriate use of AL† 78 (33.8)
*This category includes 25 nurse aids, 53 nurse assistants, 3 TB/
leprosy assistant, 3 vaccinators, 1PH dental officer, 1 entomologic 
assistant, 1 anesthetic officer and 1 laboratory technician
† Denominators for these variables do not include one health worker 
with missing valuePage 5 of 10
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versely, recommended CQ and quinine dosage prescrip-
tions were less common (17/32; 53% and 27/48; 56%).
For 669 patients who had AL dispensed at the health facil-
ity (Table 4), health workers variably performed dispens-
ing and counseling tasks: 51% had weight measured, 97%
were explained how to take AL at home, 67% were advised
to complete all doses, 47% were instructed to take drug
after the meal, 15% received the first dose of AL while at
the facility, 14% were observed while swallowing the first
dose, and only 7% were advised what do in case of vom-
iting. Interestingly, apart from measuring the weight
which health workers more commonly performed for
children < 5 years of age (65%) than in patients 5 years
and older (41%), there was no significant difference
between age groups in the performance of any other dis-
pensing and counseling tasks (Table 4).
Factors influencing quality of AL case-management
Eleven factors and six interaction terms that may have
influenced health workers decisions to 1) treat for
malaria, and 2) select recommended AL treatment at facil-
ities where AL was in stock on the survey day were exam-
ined. Table 5 presents multivariate results for statistically
significant associations (P-value < 0.05) between exam-
ined factors and each outcome, and univariate results for
factors which did not meet the criteria for multivariate
analysis (P-value < 0.15) or were statistically non-signifi-
cant to be retained in final models.
Table 3: Antimalarial treatments for patients who needed management with AL as defined by national guidelines
All health facilities < 5 years (N = 461) ≥ 5 years (N = 739) All patients (N = 1200)
n (%) 95% CI n (%) 95% CI n (%) 95% CI
AL 306 (66.4) 61.1–71.7 415 (56.2) 50.3–62.0 721 (60.1) 55.6–64.6
CQ+SP 35 (7.6) 4.8–10.4 133 (18.0) 13.2–22.8 168 (14.0) 10.7–17.3
Quinine 27 (5.9) 3.1–8.6 21 (2.8) 1.4–4.3 48 (4.0) 2.6–5.4
Chloroquine 10 (2.2) 0.7–3.6 22 (3.0) 1.4–4.6 32 (2.7) 1.5–3.9
SP 2 (0.4) 0–1.0 7 (1.0) 0–2.1 9 (0.8) 0–1.5
Other antimalarial treatments* 16 (3.5) 1.4–5.6 14 (1.9) 0.5–3.3 30 (2.5) 1.2–3.8
No antimalarial prescribed 65 (14.1) 10.8–17.4 127 (17.2) 13.9–20.5 192 (16.0) 13.5–18.5
Facilities with AL in stock < 5 years (N = 428) ≥ 5 years (N = 644) All patients (N = 1072)
n (%) 95% CI n (%) 95% CI n (%) 95% CI
AL 297 (69.4) 64.2–74.6 388 (60.3) 54.2–66.3 685 (63.9) 59.5–68.3
CQ+SP 22 (5.1) 2.8–7.5 95 (14.8) 10.1–19.4 117 (10.9) 8.0–13.9
Quinine 22 (5.1) 2.4–7.9 16 (2.5) 1.0–4.0 38 (3.5) 2.2–4.9
Chloroquine 9 (2.1) 0.6–3.6 16 (2.5) 0.8–4.2 25(2.3) 1.1–3.6
SP 2 (0.5) 0–1.1 6 (0.9) 0–2.2 8 (0.8) 0–1.6
Other antimalarial treatments† 15 (3.5) 1.3–5.7 12 (1.9) 0.3–3.4 27 (2.5) 1.1–4.0
No antimalarial prescribed 61 (14.3) 10.8–17.7 111 (17.2) 13.8–20.7 172 (16.0) 13.4–18.7
* Other antimalarial treatments include artemether (2), AQ+SP (2), AL+SP (8), AL+CQ+SP (2), QN+SP (6), AL+QN (4), AL+CQ (6)
† Other antimalarial treatments include artemether (1), AQ+SP (2), AL+SP (8), AL+CQ+SP (2), QN+SP (6), AL+QN (3), AL+CQ (5)
Table 4: Quality of dispensing and counseling practices for patients who had AL dispensed
Task performed < 5 years (N = 296) ≥ 5 years (N = 373) All patients (N = 669)
n (%) 95% CI n (%) 95% CI n (%) 95% CI
Weight measured 192 (64.9) 55.9–73.8 151 (40.5) 30.9–50.1 343 (51.3) 43.2–59.4
First dose given at the facility 40 (13.5) 7.4–19.7 58 (15.6) 8.4–22.7 98 (14.7) 8.5–20.8
Swallowing of first dose observed 34 (11.5) 5.3–17.6 56 (15.0) 7.8–22.2 90(13.5) 7.3–19.7
Dosage explained 284 (96.0) 93.3–98.6 363 (97.3) 95.1–99.5 647 (96.7) 94.7–98.7
Advice provided to complete all doses 185 (62.5) 55.1–69.9 262 (70.2) 64.1–76.4 447 (66.8) 61.3–72.3
Advice provided to take drug after a meal 132 (44.6) 37.1–52.1 182 (48.8) 42.7–54.9 314 (46.9) 41.3–52.6
Advice provided what to do if vomiting 24 (8.1) 2.9–13.3 20 (5.4) 2.1–8.6 44 (6.6) 3.1–10.1Page 6 of 10
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malaria in accordance with guidelines, multivariate
results revealed significantly higher likelihood of recom-
mended practice for patients with main complaint of fever
(OR = 5.22; 95% CI: 3.61–7.54) and for those patients
seen by supervised health workers (OR = 1.63; 95% CI:
1.06–2.50). Patients were significantly less likely to be
treated for malaria if they were seen by formally qualified
health workers (OR = 0.61; 95% CI: 0.40–0.93) or if they
presented with a skin problem (OR = 0.29; 95% CI: 0.15–
0.55). Among 892 patients who were prescribed an anti-
malarial drug, AL was significantly more likely to be pre-
scribed if they were seen at facilities where on the survey
day the appropriate weight-specific AL pack was in stock
(OR = 6.15; 95% CI: 3.43–11.05) and where CQ was
absent (OR = 2.16; 95% CI: 1.09–4.28). Interestingly, no
significant association was found between any of AL
implementation activities (in-service training including
AL, access to national guidelines, and availability of
malaria wall charts) and tested outcomes (Table 5). Simi-
larly, no significant association was found with any of
outcomes for the effects of in-service training in interac-
tion terms with guidelines, wall charts, supervision, pre-
service training, availability of weight-specific AL, and
absence of CQ.
Discussion
This study of AL case-management was undertaken
approximately three years after the policy shift from
CQ+SP to AL was announced in Uganda, two years after
the beginning of implementation activities and at least a
year after AL was delivered to all facilities in study districts.
Table 5: Factors influencing health worker's practices in management of patients with artemether-lumefantrine
Outcomes and factors (No of patients in analysis*) No (%) of 
patients with outcome
% of patients 
with the outcome for 
each level of the factor
OR (95% CI) P-
value
Statistically significant factors (P < 0.05): multivariate results
Outcome 1: Health worker treats for malaria (n = 1064) 892 (83.8)
Fever main complaint (yes vs no) 88.6 vs 60.6 5.22 (3.61–7.54) < 0.001
Supervision including AL (supervised vs non-supervised HWs) 87.2 vs 82.1 1.63 (1.06–2.50) 0.027
Health worker's cadre (qualified† vs non-qualified) 82.1 vs 86.7 0.61 (0.40–0.93) 0.020
Skin problem main complaint (yes vs no) 65.3 vs 84.7 0.29 (0.15–0.55) < 0.001
Outcome 2: Health worker selects AL treatment (n = 892) 682 (76.5)
Availability of weight-specific AL pack (yes vs no) 83.8 vs 43.6 6.15 (3.43–11.05) < 0.001
Absence of chloroquine in stock (yes vs no) 84.3 vs 74.1 2.16 (1.09–4.28) 0.027
Statistically non-significant factors – univariate results
Outcome 1: Health worker treats for malaria (n = 1064) 892 (83.8)
Malaria in-service training including AL (yes vs no) 82.8 vs 87.9 0.65 (0.41–1.05) 0.078
Access to malaria guidelines (yes vs no) 84.8 vs 81.8 1.19 (0.81–1.76) 0.370
Availability of malaria wall charts (yes vs no) 83.8 vs 83.9 1.02 (0.70–1.50) 0.906
Availability of weight-specific AL pack (yes vs no) 83.5 vs 85.3 0.87 (0.49–1.55) 0.635
Absence of chloroquine in stock (yes vs no) 84.7 vs 83.6 1.06 (0.66–1.70) 0.819
Age of the patient (<5 years vs ≥ 5 years) 85.7 vs 82.6 1.27 (0.88–1.82) 0.203
Cough main complaint (yes vs no) 84.6 vs 83.0 1.09 (0.78–1.53) 0.598
Outcome 2: Health worker selects AL treatment (n = 892) 682 (76.5)
Malaria in-service training including AL (yes vs no) 77.4 vs 73.0 1.37 (0.78–2.40) 0.267
Access to malaria guidelines (yes vs no) 76.8 vs 75.6 1.12 (0.68–1.86) 0.656
Availability of malaria wall charts (yes vs no) 76.5 vs 76.4 0.93 (0.58–1.50) 0.778
Health worker's cadre (qualified† vs non-qualified) 74.8 vs 79.0 0.88 (0.55–1.41) 0.583
Supervision including AL (supervised vs non-supervised HWs) 79.6 vs 74.7 1.41 (0.85–2.32) 0.180
Age of the patient (< 5 years vs = 5 years) 81.2 vs 73.2 1.59 (1.02–2.47) 0.039
Fever main complaint (yes vs no) 75.9 vs 80.7 0.81 (0.52–1.26) 0.345
Cough main complaint (yes vs no) 79.2 vs 73.5 1.32 (0.98–1.77) 0.064
Skin problem main complaint (yes vs no) 78.1 vs 76.4 1.03 (0.43–2.47) 0.943
* 8 observations with incomplete data omitted to allow for a common denominator
† The category qualified heath workers include patients seen by doctors, nurses, clinical officers and midwives.Page 7 of 10
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become familiarized with the new guidelines and trans-
late new policy effectively into the clinical practice.
Despite the lack of universal availability of AL on the sur-
vey day (87%) and less than optimal coverage with in-
service training (79%), guidelines (68%) and AL wall
charts (48%), the overall use of AL prevailed (60%) over
non-effective CQ, SP and CQ+SP therapies (18%), or
effective, but not recommended therapies, such as qui-
nine and other antimalarial combinations (7%). The pres-
ence of study teams at facilities may have introduced a
Hawthorn effect resulting in better performance on the
survey day than usual [14,15]; however, the retrospective
review of treatment practices in a week prior to the pres-
ence of study teams suggests that this effect was relatively
minor as 52% of patients were still prescribed AL prior to
the survey. Unexpectedly, no further improvements were
observed at facilities where AL was in stock on the survey
day. At these facilities two main practices discordant with
national recommendations are important to emphasize:
first, 20% of patients were still prescribed non-recom-
mended antimalarials, most commonly CQ+SP, and sec-
ond, further 16% of febrile patients were not treated at all
for malaria. Our explanatory analyses provide some expla-
nations that help to understand these patterns.
First, health workers were much more likely to prescribe
AL if weight-specific AL pack was in stock (OR = 6.2), but
also if non-recommended chloroquine was absent (OR =
2.2). The negative effects of the presence of ineffective
drugs on treatment practices have been described in
Kenya [16,17], and the implications of these findings are
clear – discontinuation of supply and removal of existing
stocks from facilities. More than a year after the new pol-
icy reached peripheral facilities, the absence of a stable AL
supply chain does not justify the continued supply of inef-
fective drugs.
Controversy, however, exists on the most appropriate
ways to approach common situations where tablets of AL
are in stock but not in adequate pack sizes. The strength of
all AL tablets is indeed the same, however the implemen-
tation of the AL policy includes delivery of four different
AL pack sizes (6, 12, 18 and 24 tablets) suitable for man-
agement of four different weight categories of patients (5–
14 kg; 15–24 kg; 25–34 kg and ≥ 35 kg). In Uganda there
are no instructions on what health workers should do
when only non-recommended weight-specific AL is in
stock. An ideal solution to this problem is establishment
of an effective supply chain for all four AL products; how-
ever this seems to have taken longer than anticipated.
Meanwhile, the findings of this study support recommen-
dations to instruct health workers to use AL even if ade-
quate AL pack sizes are not in stock. This temporary
practice may compromise high levels of patients' adher-
ence to AL [18], and high rates (95%) of health workers
adherence to correct AL dosing as shown in this and in the
previous studies [9,10]; however, it would still save many
lives before an effective AL supply chain is established
countrywide. If adequate availability of AL products can-
not be ensured, alternative AL preparations that do not
depend on separate packaging, should be considered and
their operational use evaluated. Finally, the implementa-
tion of parallel ACT policy promoting AS+AQ, as a stipu-
lated recommendation in national guidelines in Uganda,
might also be an option to support sufficient availability
of ACTs at the periphery of health system.
The second practice discordant with guidelines is that
16% of febrile patients are not treated with any antimalar-
ial drug; the proportion similar between young children
and patients 5 years and older. Health workers are more
likely to respect guidelines if febrile patients spontane-
ously report fever, or present without additional problems
such as skin infection. Health workers with higher qualifi-
cations and those less supervised are more likely to disre-
gard guidelines. These findings are similar to those
reported previously in Benin [19] and Kenya [16] and
continue to persist despite many studies in the past dem-
onstrating low sensitivity of various clinical signs and
symptoms to detect malaria in febrile patients across all
age groups [20-22], translation of this evidence into
national [7,12] and international guidelines [23,24], and
emphasis of series of Ugandan in-service training pro-
grammes on these guidelines [25]. This practice is more
prominent among more qualified health workers and
possibly reflects the common beliefs that their skills, and
knowledge of alternative diagnoses, could reliably distin-
guish malaria fevers from other febrile causes. The advent
of malaria rapid diagnostic tests may present an opportu-
nity not only to address well-known problem of malaria
overdiagnosis [26], but also to reduce the risk of malaria
under-treatment by promoting systematic testing of all
febrile patients.
Appropriate AL dispensing and counseling practices
deserve special attention. The performance of these tasks,
as they should be provided as part of good clinical prac-
tice, are critical to ensure high rates of patients adherence
[18] and treatment success [27,28]. In this study, we
found that nearly all patients left the facility with an expla-
nation on dosing schedule; however, administration of
the first AL dose, and provision of advice to take AL after
the meal and what to do in case of vomiting was rarely
performed across all age groups. Despite Uganda's invest-
ment in interventions to improve the quality of care such
as IMCI [25,29], deficiencies in drug dispensing and
counseling practices persist. The reasons for these subop-
timal practices are not clear and demand further qualita-Page 8 of 10
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administration of first AL dose in the absence of food, the
effects of lack of potable water on administering drugs at
peripheral facilities and the effects of AL blister packages
on the provision of replacement dose in case of vomiting.
Better understanding of these factors should guide further
interventional studies to improve dispensing and coun-
seling practices as an integral part of appropriate prescrib-
ing.
Finally, better prescribing practices could not be attrib-
uted to any routine AL implementation activities (in-serv-
ice training, guidelines, wall charts). The reviews of
previous studies with similar design, as well as systematic
reviews of other interventional trials on the use of medi-
cines in developing countries, commonly reported a
mixed association between in-service training and health
worker performance, and sometimes, as in the present
study, no association was found with any of the examined
interventions [30-32]. Unfortunately, most studies,
including this one, had only limited details about the
quality of training delivered to health workers in study set-
tings to make any definite conclusions about effectiveness
of this intervention. Yet, it seems obvious that currently
established ways of delivering ACT policies and ensuring
health workers performance during the post-delivery
period need strengthening. Prospective, interventional
studies testing cost-effectiveness of innovative types of
training, but also job-aids and supervision, and their com-
binations, should be an operational research priority of
critical importance to inform policy makers on how to
optimize the delivery of ACTs in Africa.
Conclusion
Although it was encouraging to observe that the use of AL
prevailed over non-recommended therapies in Uganda,
the quality of AL case-management is not yet optimal and
a series of deficiencies were detected at point of care. Fol-
lowing widespread ACT deployment across Africa, the pri-
ority for operational researchers and policy makers should
be to determine the most cost-effective set of interven-
tions that can be easily deployed on a larger scale to max-
imize the impact of ACTs so long as their adequate supply
to the periphery of health system can be guaranteed.
Competing interests
DZ, AT and RWS have received a fee for speaking at a
meeting organized by Novartis Pharma AG, the manufac-
turers of artemether-lumefantrine. JKT, JN, JS, JNN, SM
and JBR declared no competing interest.
Authors' contributions
DZ contributed to the conception and design of the study,
analysis, interpretation of results and finalization of the
manuscript. JKT contributed to the conception and design
of the study, supervision of data collection and interpreta-
tion of results. JN contributed to study design, supervision
of data collection and data analysis. JS and JNN contrib-
uted to data analysis and interpretation of results. JBR
contributed to data analysis, interpretation of results and
policy implications of the findings. AT contributed to the
conception and design of the study. SM contributed to
interpretation of results and policy implications of the
findings. RWS contributed to the conception and design
of the study and interpretation of results. All authors con-
tributed to drafting of the manuscript and all read and
approved the final manuscript.
Acknowledgements
This study received financial support from the COMDIS Research Pro-
gramme Consortium funded by the Department for International Develop-
ment, UK through the Malaria Consortium. RW Snow is a Wellcome Trust 
Principal Research Fellow (#079080). The authors are grateful to Moses 
Musinguzi who supervised field work at its initial stages, district health 
authorities of study districts, the field teams and to all health workers, 
patients, and caretakers of sick children who participated in the study. The 
authors are also grateful to Mike English for comments on an earlier draft. 
This paper is published with the permission of the Director of KEMRI.
References
1. Bosman A, Mendis KN: A major transition in malaria treat-
ment: the adoption and deployment of artemisinin-based
combination therapies.  Am J Trop Med Hyg 2007, 77(suppl
6):193-197.
2. Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Babirye JN, Staedke SG,
Rosenthal PJ: The comparative efficacy of chloroquine and sul-
fadoxine-pyrimethamine for the treatment of uncompli-
cated falciparum malaria in Kampala, Uganda.  Trans R Soc
Trop Med Hyg 2001, 95:50-55.
3. EANMAT: The efficacy of antimalarial monotherapies, sul-
phadoxine-pyrimethamine and amodiaquine in East Africa:
implications for sub-regional policy.  Trop Med Int Health 2003,
8:860-867.
4. Staedke SG, Mpimbaza A, Kamya MR, Nzarubara BK, Dorsey G,
Rosenthal PJ: Combination treatments for uncomplicated fal-
ciparum malaria in Kampala, Uganda: randomized clinical
trial.  Lancet 2004, 364:1950-1957.
5. Bakyaita N, Dorsey G, Yeka A, Banek K, Staedke SG, Kamya MR, Tal-
isuna A, Kironde F, Nsobya S, Kilian A, Reingold A, Rosenthal PJ,
Wabwire-Mangen F, Dorsey G: Sulfadoxine pyrimethamine plus
chloroquine or amodiaquine for uncomplicated falciparum
malaria: a randomized, multisite trial guide to national pol-
icy in Uganda.  Am J Trop Med Hyg 2005, 72:573-580.
6. Republic of Uganda: National policy on malaria treatment Malaria Con-
trol Programme, Ministry of Health; 2005. 
7. Republic of Uganda: Management of uncomplicated malaria: a practical
guide for health workers Malaria Control Programme, Ministry of
Health; 2005. 
8. Republic of Uganda: Flowchart for management of malaria Malaria Con-
trol Programme, Ministry of Health; 2005. 
9. Zurovac D, Ndhlovu M, Sipilanyambe N, Chanda P, Hamer DH,
Simon JL, Snow RW: Paediatric malaria case-management with
artemether-lumefantrine in Zambia: a repeat cross-sec-
tional study.  Malar J 2007, 6:31.
10. Zurovac D, Njogu J, Akhwale W, Hamer DH, Snow RW: Transla-
tion of artemether-lumefantrine treatment policy into pae-
diatric clinical practice: an early experience from Kenya.
Trop Med Int Health 2008, 13:99-107.
11. Okello PE, Van Bortel W, Byaruhanga AM, Correwyn A, Roelants P,
Talisuna A, D'Alessandro U, Coosemans M: Variation in malaria
transmission intensity in seven sites throughout Uganda.  Am
J Trop Med Hyg 2006, 75:219-225.Page 9 of 10
(page number not for citation purposes)
Malaria Journal 2008, 7:181 http://www.malariajournal.com/content/7/1/181Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
12. Republic of Uganda: Integrated management of childhood illnesses Minis-
try of Health; 2007. 
13. Horton NJ, Lipsitz SR: Review of software to fit generalized
estimating equation regression models.  Am Stat 1999,
53:160-169.
14. Rowe AK, Lama M, Onikpo F, Deming MS: Health worker percep-
tions of how being observed influences their practices during
consultations with ill children.  Trop 2002, 32:166-167.
15. Leonard KL, Masatu MC: The use of direct clinician observation
and vignettes for health services quality evaluation in devel-
oping countries.  Soc Sci Med 2005, 61:1944-1951.
16. Zurovac D, Rowe AK, Ochola SA, Noor AM, Midia B, English M,
Snow RW: Predictors of the quality of health worker treat-
ment practices for uncomplicated malaria at government
health facilities in Kenya.  Int J Epidemiol 2004, 33:1080-1091.
17. Wasunna B, Zurovac D, Goodman CA, Snow RW: Why don't
health workers prescribe ACT? A qualitative study of factors
affecting the prescription of artemether-lumefantrine.  Malar
J 2008, 7:29.
18. Fogg C, Bajunirwe F, Piola P, Biraro S, Grandesso F, Ruzagira E, Babi-
gumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W,
Checchi F, Guthmann JP: Adherence to a six-dose regimen of
artemether-Lumefantrine for treatment of uncomplicated
Plasmodium falciparum malaria in Uganda.  Am J Trop Med Hyg
2004, 5:525-535.
19. Rowe AK, Onikpo F, Lama M, Deming MS: Risk and protective fac-
tors for two types of error in the treatment of children with
fever at outpatient health facilities in Benin.  Int J Epidemiol
2003, 32:296-303.
20. Chandramohan D, Carneiro I, Kavishwar A, Brugha R, Desai V,
Greenwood BM: A clinical algorithm for the diagnosis of
malaria: results of an evaluation in an area of low endemicity.
Trop Med Int Health 2001, 6:505-510.
21. Chandramohan D, Jaffar S, Greenwood B: Use of clinical algo-
rithms for diagnosing malaria.  Trop Med Int Health 2002, 7:45-52.
22. Mwangi TW, Mohammed M, Dayo H, Snow RW, Marsh K: Clinical
algorithms for malaria diagnosis lack utility among people of
different age groups.  Trop Med Int 2005, 10:530-536.
23. Gove S: Integrated management of childhood illness by out-
patient health workers: technical basis and overview.  Bull
World Health Organ 1997, 75(suppl 1):7-24.
24. World Health Organization: Guidelines for the Treatment of Malaria
Global Malaria Programme; 2006. 
25. Pariyo GW, Gouws E, Bryce J, Burnham G, the Uganda IMCI impact
study team: Improving facility-based care for sick children in
Uganda: training is not enough.  Health Policy Plan 2005,
20(Suppl 1):58-68.
26. Amexo M, Tolhurst R, Barnish G, Bates I: Malaria misdiagnosis:
effects on the poor and vulnerable.  Lancet 2004, 364:1896-1898.
27. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babi-
gumira J, Kigozi I, Kiguli J, Kyomuhenda J, Ferradini L, Taylor W, Chec-
chi F, Guthmann JP: Supervised versus unsupervised intake of
six-dose artemether-lumefantrine for treatment of acute,
uncomplicated Plasmodium falciparum malaria in Mbarara,
Uganda: a randomised trial.  Lancet 2005, 365:1467-1473.
28. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley
C, Greenwood BM, Whitty CJM: Amodiaquine alone, amodi-
aquine+sulfadoxine-pyrimethamine, amodiaquine+artesu-
nate, and artemether-lumefantrine for outpatient
treatment of malaria in Tanzanian children: a four-arm ran-
domised effectiveness trial.  Lancet 2005, 365:1474-1480.
29. Gouws E, Bryce J, Habicht JP, Amaral J, Pariyo G, Chellenberg JA, Fon-
taine O: Improving antimicrobial use among health workers
in first-level facilities: results from the multi-country evalua-
tion of the Integrated Management of Childhood Illness
strategy.  Bull World Health Organ 2004, 82:509-515.
30. Ross-Degnan D, Laing R, Santoso B, Ofori-Adjei D, Diwan V, Lam-
oureux C, Hogerzeil H: Improving pharmaceutical use in primary care in
developing countries: a critical review of experience and lack of experience
Conference presentation, International Conference on Improving
Use of Medicines (ICIUM), Chiang Mai, Thailand; 1997. 
31. World Health Organization: Interventions and Strategies to Improve the
Use of Antimicrobials in Developing Countries Drug Management Pro-
gramme, Geneva; 2001. 
32. Zurovac D, Rowe AK: Quality of treatment for febrile illness
among children at outpatient facilities in sub-Saharan Africa.
Ann Trop Med Parasitol 2006, 100:283-296.Page 10 of 10
(page number not for citation purposes)
